Original Research

DOI: 10.4244/EIJ-D-24-01050

Assessment of coronary cannulation after TAVI with the Evolut FX valve: the CANNULATE TAVR EXPANDED study

Yohei Ohno1, MD; Norihiko Kamioka1, MD; Junichi Miyamoto1, MD; Ryosuke Omura1, MD; Hitomi Horinouchi1, MD; Kaho Hashimoto1, MD; Satoshi Noda1, MD; Tsutomu Murakami1, MD; Yuji Ikari1, MD; Kimiaki Okada2, MD; Marco Frazzetto3, MD; Hitesh Raheja3, MD; Hamza Lodi3, MD; Gregory Rushing3, MD; Anene Ukaigwe3, MD; Steven Filby3, MD; Sunghan Yoon3, MD; Rafey Feroze3, MD; Luis Augusto Palma Dallan3, MD, PhD; Guilherme F. Attizzani3,4, MD; on behalf of the CANNULATE TAVR EXPANDED investigators

Abstract

Background: The new-generation supra-annular, self-expanding Evolut FX system has the potential to facilitate commissural alignment.

Aims: We sought to assess the feasibility of coronary cannulation (CC) and the impact of commissural and coronary alignment on CC execution, as confirmed by post-transcatheter aortic valve implantation (TAVI) computed tomography (CT).

Methods: The CANNULATE TAVR EXPANDED study is a multicentre, prospective study which included consecutive patients who underwent transfemoral TAVI with the Evolut FX, CC, and angiography after valve deployment. Post-TAVI CT was performed to assess commissural and coronary alignment. Moderate-to-severe commissural and coronary misalignments based on the ALIGN-TAVR Consortium definition were categorised as the misalignment group. The primary endpoint was the rate of successful CC after Evolut FX implantation.

Results: A total of 126 patients were included. CC was successful in 100% of cases for the left coronary artery (LCA) and 96.7% for the right coronary artery (RCA). Moderate-to-severe commissural misalignment was observed in 13.5%, and moderate-to-severe coronary misalignment was observed in 20.6% (LCA) and 22.2% (RCA). Misaligned LCA and RCA required significantly longer CC times. In multivariable analysis, factors associated with suboptimal LCA cannulation were coronary height (odds ratio [OR] 0.73, 95% confidence interval [CI]: 0.57-0.90; p=0.006) and coronary misalignment (OR 4.58, 95% CI: 1.45-14.47; p=0.009), whereas right coronary cusp width (OR 0.63, 95% CI: 0.44-0.90; p=0.007) and coronary misalignment (OR 4.64, 95% CI: 1.29-16.74; p=0.019) were identified for the RCA.

Conclusions: High rates of CC, and commissural and coronary alignment post-TAVI with the Evolut FX were observed in this prospective, multicentre study. Coronary misalignment was identified as the strongest predictor of suboptimal CC for both the LCA and the RCA.

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 21 Number 22
Nov 14, 2025
Volume 21 Number 22
View full issue


Key metrics

Trending articles
87.2

State-of-the-Art

10.4244/EIJ-D-25-00266 Jan 19, 2026
Lesion stratification with intracoronary imaging
McGarvey M et al
free
47.45

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
34.8

Original Research

10.4244/EIJ-D-25-01006 Mar 16, 2026
Clinical outcomes and haemodynamic response after blinded stress assessment of moderate aortic stenosis
Eerdekens R et al
22.2

Viewpoint

10.4244/EIJ-D-25-01066 May 4, 2026
Intracoronary imaging guidance for de novo coronary lesion treatment with drug-coated balloons
Amabile N et al
free
20.75

Flashlight

10.4244/EIJ-D-25-01014 Apr 6, 2026
Stent retriever-assisted coronary thrombectomy with continuous aspiration
Liabot Q et al
open access
19.5

Original Research

10.4244/EIJ-D-26-00032 May 15, 2026
Glucocorticoids to reduce permanent pacemaker implantation after TAVI: the GLUCO-TAVI randomised trial
Fuertes-Kenneally L et al
19

State-of-the-Art

10.4244/EIJ-D-25-00874 Jun 1, 2026
TAVI and coronary interventions: indications, technical considerations, and clinical scenarios
Aquino Bruno H et al
free
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2026 Europa Group - All rights reserved